ARC-SUR-TILLE, France, July 6, 2026
Movmedix, the French orthopedic medical technology company behind the globally recognized LARS® synthetic ligament platform, has announced its first U.S. Food and Drug Administration (FDA) 510(k) clearance, enabling the commercial launch of its LARS® ACJ System in the United States. The milestone marks the company’s official entry into the U.S. orthopedic market and represents a significant expansion of one of the world’s most established synthetic ligament reconstruction technologies. While the initial FDA clearance specifically covers the treatment of acromioclavicular (ACJ) joint injuries, it also establishes the foundation for introducing Movmedix’s broader portfolio of ligament reconstruction and reinforcement technologies to American surgeons. Backed by more than three decades of clinical experience, over 250,000 patient implantations worldwide, and more than 100 peer-reviewed scientific publications, the LARS® platform has become one of the most extensively validated synthetic ligament technologies used across multiple orthopedic applications. The FDA clearance further strengthens Movmedix’s global expansion strategy while increasing access to advanced minimally invasive solutions for patients suffering from ligament injuries.
FDA Clearance Brings Proven LARS® Ligament Technology to the U.S.
The newly granted FDA 510(k) clearance authorizes commercialization of the LARS® ACJ System for treating acromioclavicular joint injuries, one of the most common shoulder injuries affecting athletes and physically active individuals. Although this initial authorization focuses on the shoulder, Movmedix emphasized that the approval represents the first step toward introducing its complete synthetic ligament technology platform into the United States. Built around the company’s proprietary LARS® free-fiber technology, the platform has demonstrated long-term clinical performance across 11 orthopedic indications, particularly in ligament reconstruction and reinforcement procedures.
Unlike conventional graft-based approaches, synthetic ligament technologies are designed to provide immediate mechanical stability while supporting tissue integration and faster functional recovery. The company believes growing demand for innovative orthopedic solutions, particularly among sports medicine specialists, military personnel, and active populations, creates significant opportunities for expanding the adoption of LARS® technology across the U.S. healthcare market.
Growing Burden of Ligament Injuries Drives Demand for Advanced Orthopedic Solutions
Advertisement
Ligament injuries continue to represent a major global healthcare challenge, particularly among younger, physically active individuals. In the United States alone, more than 200,000 anterior cruciate ligament (ACL) injuries occur annually, often requiring surgery followed by months of rehabilitation while increasing the long-term risk of osteoarthritis. Acromioclavicular joint dislocations also account for approximately 10% of all shoulder injuries, with particularly high incidence among athletes participating in football, rugby, wrestling, and ice hockey. As healthcare providers increasingly seek treatment options that improve recovery while restoring joint stability, synthetic ligament technologies have attracted growing clinical interest.
Supported by decades of clinical experience, the LARS® platform offers orthopedic surgeons an additional option for reconstructing damaged ligaments while maintaining mechanical strength and supporting long-term patient mobility. Company leadership noted that restoring mobility remains one of the most important factors influencing long-term quality of life, making continued innovation in orthopedic reconstruction increasingly important as sports participation and active lifestyles continue to expand worldwide.
Movmedix Expands Global Orthopedic Innovation Strategy
The FDA milestone represents another important step in Movmedix’s international growth strategy. Headquartered near Dijon, France, the company has rapidly expanded its global presence, now serving healthcare providers in 36 countries while generating significant commercial growth since 2021. Building upon its expertise in advanced textile engineering, biomaterials, and orthopedic implant technology, Movmedix plans to establish a dedicated U.S. presence through strategic partnerships with orthopedic surgeons, sports medicine specialists, distributors, and healthcare institutions.
The company also intends to pursue additional FDA submissions covering other products within the broader LARS® portfolio, supporting long-term expansion across multiple orthopedic applications. As demand continues to increase for minimally invasive orthopedic technologies that improve patient outcomes, Movmedix remains committed to advancing scientific innovation, clinical education, and evidence-based orthopedic care while strengthening its position as a global leader in ligament reconstruction and reinforcement technologies.
Source: Movmedix press release
